Search results

Skip to results

Type

Status

Last updated

Your search for Cemiplimab Metastitic Cervical Cancer returned no results
Showing 1 result for cemiplimab metastatic cervical cancer

  1. Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) (TA901)

    NICE is unable to make a recommendation on cemiplimab (Libtayo) for treating recurrent or metastatic cervical cancer in adults because Sanofi did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    20 June 2023

    Sections for TA901